(RTTNews) - PolyPid Ltd. (PYPD), an innovative biopharmaceutical company developing long-acting, controlled-release therapies, reported second-quarter 2026 financial results and corporate updates, highlighting FDA acceptance of D-PLEX100's NDA with Priority Review and a commercialization partnership with Azurity Pharmaceuticals.
Company Profile
PolyPid focuses on developing localized, controlled-release therapies designed to improve treatment effectiveness at the site of care. Its lead program, D-PLEX100, is being developed to prevent surgical site infections following abdominal colorectal surgery.
Pipeline Update
D-PLEX100 for Surgical Site Infections
On June 1, 2026, PolyPid completed its NDA submission for D-PLEX100, supported by positive Phase 3 SHIELD II results showing a 60% relative risk reduction in surgical site infections compared with standard of care.
Following the quarter, the FDA accepted the NDA and granted Priority Review, with a PDUFA goal date of November 28, 2026.
PolyPid remains on track to submit a Marketing Authorization Application to the European Medicines Agency in Q3 2026.
Commercialization Partnership
PolyPid entered into an exclusive U.S. and Canada commercialization partnership with Azurity Pharmaceuticals in July 2026.
Following FDA acceptance of the NDA, PolyPid achieved milestones triggering $30 million in upfront and near-term payments. The agreement provides eligibility for approximately $320 million in total upfront and milestone payments, along with tiered royalties ranging from the mid-teens to mid-twenties percentages on U.S. and Canadian sales.
Azurity is targeting a potential U.S. commercial launch of D-PLEX100 in early 2027 and will fund clinical development supporting potential label expansion.
Kynatrix Pipeline
PolyPid continues to advance its proprietary Kynatrix technology beyond D-PLEX100, including a long-acting metabolic program and additional infection-prevention opportunities.
Q2 2026 Financial Results
For the second quarter ended June 30, 2026, PolyPid reported R&D expenses of $6.1 million, compared with $6.2 million in Q2 2025.
G&A expenses were $1.3 million, compared with $2.5 million in the prior-year quarter, while marketing and business development expenses were $0.5 million, compared with $0.7 million.
PolyPid reported a net loss of $7.8 million, or $0.35 per share, compared with a net loss of $10.0 million, or $0.78 per share, in Q2 2025.
Cash Position
PolyPid held $6.6 million in cash and cash equivalents as of June 30, 2026.
Including expected proceeds from the Azurity partnership and potential future payments, the company believes it can fund operations into 2028.
Business Update
FDA Priority Review of D-PLEX100, the $30 million in confirmed Azurity payments and the planned European regulatory submission represent key near-term milestones for PolyPid.
The company is preparing for a potential U.S. commercial launch in early 2027 while continuing to advance D-PLEX100 toward additional surgical indications and develop its broader Kynatrix pipeline.
PYPD is currently trading at $4.67, down 1.27%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
